NCT04262141 is a Phase 2 clinical trial of IMG-7289 in Essential Thrombocythemia, sponsored by Terrence J Bradley, MD.

Who is sponsoring NCT04262141?

NCT04262141 is sponsored by Terrence J Bradley, MD.

What drugs are being tested in NCT04262141?

Interventions in NCT04262141: IMG-7289.

What condition does NCT04262141 study?

NCT04262141 studies Essential Thrombocythemia, Polycythemia Vera.

Is NCT04262141 still recruiting?

NCT04262141 is currently active, enrolled. Last updated 7 January 2026.

Last reviewed 2026-01-07 · How we verify

NCT04262141

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Active, enrolled Phase 2 Last updated 7 January 2026

What this trial tests

Phase 2 trial testing IMG-7289 in Essential Thrombocythemia in 4 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 October 2020

Primary endpoint
31 October 2026

31 October 2027

Quick facts

Lead sponsor	Terrence J Bradley, MD
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	2 October 2020
Primary completion	31 October 2026
Estimated completion	31 October 2027
Sites	1 location across United States

Drugs / interventions tested

IMG-7289 — full drug profile →

Conditions studied

Essential Thrombocythemia — all drugs for Essential Thrombocythemia →
Polycythemia Vera — all drugs for Polycythemia Vera →

Sponsor

Terrence J Bradley, MD

Who can join

18 and older, any sex, with Essential Thrombocythemia or Polycythemia Vera. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators to overcome drug resistance in cancers.
Wang N, Ma T, Yu B, Yu B. · · 2023 · cited 213× · PMID 36797239 · DOI 10.1038/s41392-023-01341-7
LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Noce B, Di Bello E, Fioravanti R, Mai A. · · 2023 · cited 78× · PMID 36817147 · DOI 10.3389/fphar.2023.1120911
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias AM, Lammers T, et al · · 2021 · cited 50× · PMID 34944059 · DOI 10.3390/cells10123551
Novel therapeutics in myeloproliferative neoplasms.
Venugopal S, Mascarenhas J. · · 2020 · cited 32× · PMID 33267911 · DOI 10.1186/s13045-020-00995-y
Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms.
Brkic S, Meyer SC. · · 2021 · cited 26× · PMID 33403355 · DOI 10.1097/hs9.0000000000000516
Genomics of MPN progression.
Patel AA, Odenike O. · · 2020 · cited 14× · PMID 33275731 · DOI 10.1182/hematology.2020000129
Biological and therapeutic role of LSD1 in Alzheimer's diseases.
Li Y, Zhao Y, Li X, Zhai L, et al · · 2022 · cited 12× · PMID 36386192 · DOI 10.3389/fphar.2022.1020556
Polycythemia Vera (PV): Update on Emerging Treatment Options.
Benevolo G, Vassallo F, Urbino I, Giai V. · · 2021 · cited 9× · PMID 33758507 · DOI 10.2147/tcrm.s213020

Verify or expand the search:

Other trials of IMG-7289

Trials testing the same drug.

NCT04081220 — Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 · Phase 2 · active not recruiting

Other recruiting trials for Essential Thrombocythemia

Currently open trials in the same condition.

NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
NCT06734637 — Efficacy and Safety of Peginterferon in ET and PV. · NA · recruiting
NCT06456346 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) · Phase 3 · recruiting
NCT06361641 — Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes · NA · recruiting
NCT06378437 — A Study of GLB-001 in Patients With Myeloid Malignancies · Phase 1 · recruiting

Other Terrence J Bradley, MD trials

Trials by the same sponsor.

NCT05597306 — Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04262141 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Terrence J Bradley, MD
Last refreshed: 7 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04262141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing